Genome International

What Genome International does

Genome International Corporation (GIC) is a Madison, Wisconsin-based Bio-IT company founded in 1992 by Dr. Periannan Senapathy. The company develops cloud-based clinical genomics software that performs whole-genome analysis and clinical decision support for hospitals, diagnostic laboratories, pharmaceutical companies, and academic research institutions. Its core product, Genome Explorer, analyzes 100% of the human genome, including non-coding regions where more than 60% of disease-causing mutations occur, and integrates diagnosis, therapeutics, pharmacogenomics, and patient EHR data into a single platform. Underlying the platform is the proprietary Shapiro-Senapathy (S&S) algorithm for splice-site mutation discovery, cited in over 6,000 peer-reviewed publications.

The company's product portfolio spans Genome Explorer (cloud clinical decision support), GenomeAI (AI-driven variant interpretation and custom pipelines), Cohort Genome Explorer (population genomics), Family Genome Analysis Platform (hereditary pattern analysis), and the S&S Algorithm as a standalone IP asset. The company also operates a Talent Solutions division providing IT staffing across application development, cloud, infrastructure, security, and legacy systems. Revenue derives from enterprise subscriptions for the genomics platform, custom software development, and professional staffing services. The company maintains ISO 27001, HIPAA, GDPR, and EU MDR compliance, enabling sales into regulated clinical and EU markets. No external funding rounds, M&A activity, or institutional investors are disclosed; the company appears bootstrapped and founder-led.

GIC targets four primary verticals: hospitals (precision medicine and clinical reporting), diagnostic labs (molecular diagnostics and ACMG/AMP-aligned reporting), pharmaceutical companies (drug response gene identification and clinical trial genomics), and research institutions (cohort and population genomics). Pricing is quote-based with 'Request a Demo' and free trial CTAs on the website, consistent with an enterprise sales-assisted GTM motion. Customer logos on the website are not specifically named, and no revenue, ARR, or headcount-growth figures are publicly disclosed, limiting visibility into commercial scale.

Name

Genome International

Legal name

Genome International Corporation

Website

https://genome.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

51–100 employees

Short description

Genome International Corporation is a Madison, Wisconsin-based Bio-IT company founded in 1992 that builds cloud-based clinical genomics software, including Genome Explorer and the proprietary Shapiro-Senapathy algorithm, to serve hospitals, diagnostic labs, pharmaceutical companies, and research institutions with whole-genome analysis and clinical decision support.

Ownership category

akta.pro rank

Product category

Clinical Genomics Software

NAICS

Computer Systems Design and Related Services (54151), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

akta.pro secondary industries

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Clinical genomics software
• Whole genome analysis
• Precision medicine platform
• IT staffing services
• Splice site mutation detection

Headquarters

HQ city

Madison

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Genome Explorer Platform Subscription: Cloud-based clinical genomics platform sold to hospitals, diagnostic labs, pharmaceutical companies, and research institutions. The platform appears to be sold as an enterprise subscription with demonstration and trial evaluation periods.
2. IT Staffing and Talent Solutions: The company provides IT staffing services including application development staffing, cloud computing staffing, IT infrastructure & security staffing, and legacy staffing. Services include contract, permanent, and on-demand staffing arrangements.
3. Custom Software Development: GenomeAI specializes in designing, developing, and programming custom computer software for genomic analysis, tailored to the unique needs of researchers, healthcare providers, and biotech companies.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Genome International Corporation sells a cloud-based clinical genomics platform called Genome Explorer that performs rapid whole genome analysis and delivers clinical decision support to hospitals, diagnostic labs, pharmaceutical companies, and research institutions. The platform analyzes 100% of the human genome (coding and non-coding regions) using proprietary algorithms including the Shapiro-Senapathy (S&S) algorithm for splice site mutation discovery, and integrates diagnosis, therapeutics, pharmacogenomics, and EHR data into a single clinical report. The company also provides GenomeAI for AI-driven genomic analysis solutions and Talent Solutions for IT staffing services.

Product overview

Genome International offers a unified cloud-based clinical genomics platform called Genome Explorer, which integrates whole genome analysis, clinical decision support, cohort genomics, and family genomics into a single system. The platform is powered by proprietary algorithms including the Shapiro-Senapathy (S&S) Algorithm for splice site mutation discovery. The company also provides GenomeAI for AI-driven genomic analysis solutions and Talent Solutions for IT staffing services. The company serves hospitals, diagnostic labs, researchers, and pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Brands

• Genome Explorer®: Clinical genomics platform for precision medicine - a cloud-based clinical decision support system that analyzes patient whole genomes to discover genetic causes of disease and improve treatment.
• GenomeAITM
• Shapiro-Senapathy (S&S) Algorithm
• Cohort Genome ExplorerTM
• Family Genome Analysis Platform

Products and services

• Genome Explorer A cloud-based clinical genomics platform for precision medicine that performs rapid whole genome analysis and provides clinical decision support for clinicians and molecular diagnostic specialists. It integrates diagnosis, therapeutics, pharmacogenomics, and EHR data into a single platform and is used by hospitals, diagnostic labs, pharmaceutical companies, and research institutions.
• GenomeAI An AI-powered software offering specializing in customized genomic analysis solutions using artificial intelligence and machine learning for variant interpretation, pattern recognition, genomic data annotation, and custom pipelines for researchers, healthcare providers, and biotech companies.
• Shapiro-Senapathy (S&S) Algorithm A proprietary algorithm developed by founder Dr. Periannan Senapathy for discovering splice site mutations in disease-causing genes and predicting the effects of mutations found in real splice sites and cryptic splice sites. Cited in over 6,000 peer-reviewed research articles and is the most widely used clinical genomics algorithm globally.
• Talent Solutions IT staffing services providing contract, permanent, and on-demand professionals for application development, cloud computing, IT infrastructure and security, and legacy systems across various industries.

Quantifiable outcome

• Analysis time reduced from months/years to days for cohort analysis
• +2 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Fabric Genomics: Fabric Genomics delivers AI-driven clinical genomic interpretation for inherited disease and oncology, with a focus on whole-genome analysis — a direct competitor to Genome Explorer's clinical interpretation capabilities.
• SOPHiA Genetics: SOPHiA Genetics offers a clinical genomics interpretation platform (SOPHiA DDM) used by hospitals and labs for variant analysis and clinical reporting — a direct functional parallel to Genome Explorer's clinical decision support role.
• Velsera (formerly Seven Bridges): Velsera provides a genomics analysis platform used by clinical labs and pharma for secondary/tertiary analysis, cohort exploration, and clinical reporting — a close functional comparable to Genome Explorer and Cohort Genome Explorer.
• DNAnexus: DNAnexus is a cloud-based genomics data analysis and collaboration platform serving pharma, clinical, and research customers — a direct infrastructure-and-software parallel to Genome International's cloud platform.
• Congenica: Congenica provides a clinical genomics data analysis platform for rare disease and inherited disorder interpretation, directly comparable to Genome International's whole-genome clinical decision support offering.

Emerging players

• Lifebit: Lifebit provides a cloud-based, AI-driven genomics platform for federated analysis across pharma, research, and clinical customers — a comparable next-generation genomics platform targeting similar enterprise buyers.
• BC Platforms: BC Platforms offers a genomics data management and analysis platform used by pharma, biobanks, and research institutions — a comparable enterprise genomics-software business model to Genome International's cohort and pharma offerings.
• Tempus Labs: Tempus combines AI-driven NGS analysis with clinical decision support for oncology and pharmacogenomics, overlapping with Genome Explorer's therapeutic and drug-response use cases while operating at significantly larger scale.

Broad incumbents

• Illumina (DRAGEN / BaseSpace): Illumina's DRAGEN and BaseSpace provide secondary and tertiary genomic analysis tightly integrated with its sequencers — a broad incumbent that competes at the upstream analysis layer where Genome Explorer also operates.
• QIAGEN (QCI / QIAGEN Clinical Insight): QIAGEN Clinical Insight is an established clinical variant interpretation platform embedded within a much larger life-sciences tools portfolio, offering overlapping but broader capabilities than Genome International's specialist platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/genomeintl

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genome International